Scandinavian Biolabs (SBL), a Danish innovator within the haircare business, introduced the closing of a €4 million funding spherical led by Auréa Group marking a big milestone alongside the corporate’s development journey. Auréa joins present buyers Blazar Capital on the board of SBL.
Based in 2020, Scandinavian Biolabs has established itself as a pacesetter in science-backed, non-invasive, preventative merchandise focusing on early-stage hair loss. The corporate’s flagship product, the Bio-Pilixin® Activation Serum, has been a game-changer out there, and has been clinically examined for its optimistic results.
Scandinavian Biolabs initially launched as a direct-to-consumer (DTC) model, quickly constructing a loyal buyer base by way of its on-line platform. Constructing on this success, the model has expanded into retail, and varied pharmacies throughout a number of geographies.
Anders Reckendorff, CEO and Co-Founding father of Scandinavian Biolabs, mentioned: “We’ve constructed a robust basis with our modern merchandise and confirmed that if we are able to present our clients worth and outcomes, we can even have a robust enterprise. We’re excited to be joined by our new buyers who might help us leapfrog our development by way of their expertise and know-how.”
With over 140,000 clients supported thus far, and a Trustpilot rating of 4.5 out of 5, Scandinavian Biolabs is on a quick monitor to grow to be the popular answer for dependable, examined and sincere hair-care merchandise that work along with your physique. SevenVentures (A part of Professional. SiebenSat.1 Group) is supporting the German growth by way of a strategic TV collaboration.
The €4 million money infusion from Auréa will allow Scandinavian Biolabs to pursue its formidable development plans extra aggressively forging a management place within the UK, Germany, and the Nordics, whereas additionally getting into the US market, scaling the enterprise by way of an internet providing, and increasing strategic retail akin to pharmacies.
Auréa Fund commented: “Auréa is delighted to have been chosen by the Scandinavian Biolabs as their most well-liked investor for the expertise and operational value-add that we deliver along with the expansion capital. We imagine within the founders and the really differentiated and efficacious merchandise that they’ve developed. We’re assured that collectively we are going to scale this into a big worldwide model.”
